Hypertension is a major modifiable risk factor for Alzheimer’s disease and related dementias (ADRD). The authors sought to determine whether predominant use of antihypertensive medication classes that are predicted to stimulate angiotensin II type 2 and type 4 receptor signaling differs in association with incident ADRD compared with classes that inhibit those receptors. Prior pharmacoepidemiologic evidence relied largely on a single Medicare cohort, motivating external replication across independent healthcare data environments.
The investigation used a retrospective new-user, active-comparator cohort design with propensity score matching, implemented in parallel across two structurally independent data sources: the Vanderbilt University Medical Center Synthetic Derivative (VUMC SD), a deidentified academic medical center electronic health record resource with data through February 2025, and the Merative MarketScan Medicare Database covering 2015 to 2023. Analyses in each data source applied the same conceptual design to enable external replication.
Eligible participants were adults aged 65 years or older with a diagnosis of hypertension and at least a 365-day blanking period prior to cohort entry. Participants were required to have at least 365 cumulative days of antihypertensive exposure after the blanking period. Predominant use of a medication class was defined as at least 80% of cumulative exposure days attributable to that class.
Exposure groups were categorized as:
The primary outcome was time to first incident ADRD diagnosis. Incident ADRD was identified using ICD-9 and ICD-10 diagnosis codes consistent with the CMS Chronic Conditions Data Warehouse definition. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models incorporating time-dependent covariates. The study also used propensity score matching as part of the active-comparator new-user design to address baseline confounding.
The Medicare cohort included 1,596,034 beneficiaries with a mean (SD) age of 75.0 (8.0) years; 55% were female. The VUMC SD cohort included 80,267 patients with a mean (SD) age of 72.3 (5.8) years; 57% were female. Follow-up extended approximately 7 years on average across cohorts, during which incident ADRD events were ascertained.
Crude ADRD incidence over the follow-up period was lower among predominant users of receptor-stimulating medications than among predominant users of receptor-inhibiting medications in both datasets (Medicare: 6.7% vs 8.2%; VUMC SD: 4.9% vs 5.7%).
After adjustment, predominant use of stimulating medications was associated with a modestly lower risk of incident ADRD compared with inhibiting medications in both cohorts:
These parallel effect estimates across two distinct data environments support replication of the association.
Established cardiovascular and neuropsychiatric risk factors—specifically atrial fibrillation, heart failure, chronic kidney disease, and depression—demonstrated expected associations with ADRD risk in both cohorts. The consistency of these known risk factor associations across datasets was noted by the authors as supporting internal validity of the analyses.
Across two structurally independent healthcare data sources, predominant use of antihypertensive medication classes expected to stimulate angiotensin II type 2 and type 4 receptor signaling was associated with a modestly lower risk of incident ADRD compared with predominant use of receptor-inhibiting agents. By replicating findings in both Medicare claims and an academic medical center EHR, the study extends prior single-source pharmacoepidemiologic evidence. The authors suggest these results support further evaluation of receptor-targeted antihypertensive strategies for cognitive outcomes in randomized comparative-effectiveness trials.
The abstract reports the study design, exposures, outcomes, and principal results but does not provide full details of some analytic decisions and secondary analyses in the source summary. Certain data used in the Medicare analyses were supplied by Merative MarketScan Research Databases; the authors note that any analysis and interpretation based on those data are solely the authors’ responsibility. The source indicates NIH Common Fund support (R01AG069900). No competing interests were declared.